AC
CLGN icon

Armistice Capital’s CollPlant Biotechnologies CLGN Stock Holding History

Armistice Capital’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,400
Closed -$34.3K – 351
2026
Q1 		$34.3K Buy
+6,400
New +$64.6K ﹤0.01% 252

Other funds holding CLGN

PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $243M AUM 8.27% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Armistice Capital's CLGN Position: Q2 2026 in Review

Armistice Capital sold out of CollPlant Biotechnologies (CLGN) in Q2 2026, closing a stake of 6,400 shares — an estimated $34.3K sold.

Armistice Capital first reported a position in CLGN in Q1 2026 and held it in 1 quarter. The position peaked at $34.3K in Q1 2026. 15 funds tracked by Wall St. Rank hold CLGN as of Q2 2026.

  • Armistice Capital reported no remaining CollPlant Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 6,400 CollPlant Biotechnologies shares in Q2 2026, an estimated $34.3K.
  • Armistice Capital first reported a position in CollPlant Biotechnologies in Q1 2026 and held it in 1 quarter.
  • Armistice Capital's CollPlant Biotechnologies position peaked at $34.3K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.